To address these questions, we have analyzed changes in the levels of serum PICP and CITP:MMP-1, and of biomarkers associated with myocardial injury-dysfunction (hs-TnT and NT-proBNP) in BC patients before ACC and at post-treatment visits up to 12 months after ACC completion. This evidence concerns the gene MMP1 and adrenal cortex carcinoma.